Company:  CALADRIUS BIOSCIENCES, IN ... (CLBS)
Form Type:  10-K
Filing Date:  3/14/2019 
CIK:  0000320017 
Address:  110 ALLEN ROAD
SECOND FLOOR
 
City, State, Zip:  BASKING RIDGE, New Jersey 07920 
Telephone:  908-842-0100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.35  
Change: 
-0.18 (-7.12%)  
Trade Time: 
Aug 16  
Market Cap: 
$24.44M
Trade CLBS now with

© 2019  
Description of Business
Caladrius Biosciences, Inc. ("we," "us," "our," "Caladrius" or the "Company") is a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular medicine and cell therapy, among other areas. Our goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, in Phase 2 and eligible for early conditional approval in Japan for the treatment of critical limb ischemia ("CLI"); CLBS14-CMD, in Phase 2 in the U.S.
Register and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS.
      ITEM 1A. RISK FACTORS.
      ITEM 1B. UNRESOLVED STAFF COMMENTS.
      ITEM 2. PROPERTIES.
      ITEM 3. LEGAL PROCEEDINGS.
      ITEM 4. MINE SAFETY DISCLOSURES.
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA.
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Note 11 - Share-Based Compensation
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES.
      ITEM 9B. OTHER INFORMATION.
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.32
  EXHIBIT 14.1
  EXHIBIT 21.1
    SUBSIDIARIES
  EXHIBIT 23.1
    CONSENT OF INDEPENENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATIONS UNDER SECTION 302
  EXHIBIT 31.2
    CERTIFICATIONS UNDER SECTION 302
  EXHIBIT 32
    CERTIFICATIONS UNDER SECTION 906